Head-to-head · WeighScore
Spry vs Teleios Health
The verdict
Teleios Health takes it — 60.2/100 to 56.8/100.
Teleios Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Teleios Health is a physician-led, cash-pay GLP-1 weight-loss platform marketing compounded semaglutide from $99/mo and compounded tirzepatide from $139/mo, delivered direct to your door through a fully…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Spry | Teleios Health |
|---|---|---|
| WeighScore | 56.8/100 | 60.2/100 |
| Grade | C | C |
| Scorecard rank | #408 | #327 |
| Semaglutide | $199/mo (starting dose, compounded) | $99/mo (starting dose, compounded) |
| Tirzepatide | $299/mo (starting dose, compounded) | $139/mo (starting dose, compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #408 · C
Strengths
- Three named co-founders disclosed (Gabriel Mullins, Sara Yoder, Tyler Bowman) — better-than-average transparency
- Pricing shown on the homepage ($199 semaglutide / $299 tirzepatide / $249–$299 peptides) — no full sign-up wall
- Broader range (2 GLP-1s plus 3 anti-aging peptides) appeals to longevity buyers
- No contracts or commitment required
- LegitScript Certified with a public verification link
Where it loses points
- Displays an "FDA Approved" badge though compounded GLP-1s are not FDA-approved finished drugs — potentially misleading
- Intake reviewed by a nurse practitioner, not an MD
- States served not disclosed publicly
- Pharmacy partner not named, and 503A vs 503B designation not specified
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Graded #327 · C
Strengths
- Compounded semaglutide from $99/mo — among the lowest floor prices in cash-pay telehealth
- Compounded tirzepatide from a competitive $139/mo floor
- Markets physician (MD/DO) prescribing rather than an NP-only model
- Clean meta-tag and SEO implementation
Where it loses points
- Single-page app: state availability, pharmacy partner, dose pricing, lab requirements, and refund policy aren't visible and couldn't be verified
- No named medical director, physician, or corporate entity disclosed
- Year founded unknown — a newer floor-price entrant warranting extra scrutiny
- No LegitScript, NABP, or SOC 2 trust signal found
- Heavy paid-acquisition ad-tech stack — pair with diligence on the clinical layer
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.